Log In
Print
BCIQ
Print
Print this Print this
 

Sovaldi, sofosbuvir (GS-7977) (formerly PSI-7977)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionNucleotide analog HCV NS5B polymerase inhibitor
Molecular Target HCV NS5B polymerase
Mechanism of ActionViral polymerase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis C virus (HCV)
Indication DetailsPrevent recurrent chronic HCV infection following liver transplantation; Treat chronic HCV genotype 1 infection in patients who failed prior therapy; Treat chronic HCV genotype 1 or 4 infection; Treat chronic HCV genotype 1, 2 and 3 infection in treatment-naïve patients; Treat chronic HCV genotype 1, 4, 5 and 6 infection in treatment-naïve patients; Treat chronic HCV genotype 2 and 3 infection in treatment-naïve patients; Treat chronic HCV genotype 2 infection; Treat chronic HCV genotypes 2 and 3 infection in treatment-experienced patients; Treat chronic HCV genotypes 2 or 3 infection; Treat chronic HCV infection; Treat chronic HCV infection in patients co-infected with HIV; Treat chronic HCV infection in patients with cirrhosis and portal hypertension with or without liver decompensation; Treat chronic HCV infection in treatment-naïve patients; Treat cirrhotic patients with chronic HCV genotype 1 infection; Treat HCV genotype 1 infection; Treat HCV genotype 1, 2 or 3 infection in patients co-infected with HIV; Treat HCV genotype 3 infection; Treat HCV infection; Treat HCV infection in cirrhotic patients and patients with post-liver transplant HCV recurrence; Treat non-cirrhotic patients with chronic HCV genotype 1 infection; Treat recurrent chronic HCV infection following liver transplantation
Regulatory Designation U.S. - Breakthrough Therapy (Treat chronic HCV infection);
U.S. - Fast Track (Treat chronic HCV infection);
U.S. - Priority Review (Treat chronic HCV infection);
EU - Accelerated Assessment (Treat chronic HCV infection);
Japan - Standard Review (Treat chronic HCV genotype 2 infection)
Partner Mylan N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

10

$11,200.0M

$11,200.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today